| Trial ID: | L1481 |
| Source ID: | NCT05713851
|
| Associated Drug: |
Dapagliflozin
|
| Title: |
Dapaglifozin to Avoid Acute Kindey Injury (AKI) to Chronic Kidney Disease (CKD) Transition: DAKI-CKD Study
|
| Acronym: |
DAKI-CKD
|
| Status: |
RECRUITING
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
AKI - Acute Kidney Injury|Biomarkers|Transition to CKD|CKD
|
| Interventions: |
DRUG: Dapagliflozin
|
| Outcome Measures: |
Primary: The primary outcome will be the mean change in urinary Serpin A3 (uSerpinA3) levels 18 months after randomization of the patients., 18 months | Secondary: GFR at 18 months of randomization calcutated with CKD-EPI creatinine-Cystatin C Equation., 18 months|Urine HSP-72 levels 18 months after randomization of the patients, 18 months|Urine NGAL levels 18 months after randomization of the patients, 18 months|Urine KIM-1 levels 18 months after randomization of the patients, 18 months|Serum Cystatin C levels 18 months after randomization of the patients, 18 months|Serum creatinine levels 18 months after randomization of the patients, 18 months
|
| Sponsor/Collaborators: |
Sponsor: Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran | Collaborators: Olynka Vega Vega|Noemi del Toro Cisneros|Miguel Ángel Martínez Rojas
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE2|PHASE3
|
| Enrollment: |
100
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION
|
| Start Date: |
2023-01-01
|
| Completion Date: |
2025-01-01
|
| Results First Posted: |
|
| Last Update Posted: |
2024-03-05
|
| Locations: |
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, 14080, Mexico
|
| URL: |
https://clinicaltrials.gov/show/NCT05713851
|
